Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Wainberg

Showing results (21-30 of 341) with videos related to

Pageof 35
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2015
Editorial Commentary: Clinical Significance of HIV Subtype Variability in Regard to Treatment OutcomeMark A Wainberg
Journal of the International AIDS Society|October 15, 2009
The 16th International Conference on AIDS: Will It Leave a Legacy?Helene Gayle, Mark A Wainberg
Viruses|July 23, 2015
Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistenceThibault Mesplède, Mark A Wainberg
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|October 15, 2003
Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategyMike Youle, Mark A Wainberg
Journal of the International AIDS Society|December 8, 2015
Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapyMark A Wainberg, Thibault Mesplede
Infectious Diseases and Therapy|August 20, 2014
Integrase Strand Transfer Inhibitors in HIV TherapyThibault Mesplède, Mark A Wainberg
Retrovirology|February 10, 2007
Impact of the 16th International Conference on AIDS: can these conferences lead to policy change?Helene Gayle, Mark A Wainberg
AIDS Reviews|June 2, 2006
HIV transmission and primary drug resistanceDan Turner, Mark A Wainberg
AIDS (London, England)|February 16, 2010
Can the further clinical development of bevirimat be justified?Mark A Wainberg, Jan Albert
AIDS Patient Care and Stds|October 9, 2007
Review: immunologic response to protease inhibitor-based highly active antiretroviral therapy: a reviewMark A Wainberg, Bonaventura Clotet
Pageof 35

Showing results (21-30 of 341) with videos related to

Sort By:
Pageof 35
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2015
Editorial Commentary: Clinical Significance of HIV Subtype Variability in Regard to Treatment OutcomeMark A Wainberg
Journal of the International AIDS Society|October 15, 2009
The 16th International Conference on AIDS: Will It Leave a Legacy?Helene Gayle, Mark A Wainberg
Viruses|July 23, 2015
Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistenceThibault Mesplède, Mark A Wainberg
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|October 15, 2003
Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategyMike Youle, Mark A Wainberg
Journal of the International AIDS Society|December 8, 2015
Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapyMark A Wainberg, Thibault Mesplede
Infectious Diseases and Therapy|August 20, 2014
Integrase Strand Transfer Inhibitors in HIV TherapyThibault Mesplède, Mark A Wainberg
Retrovirology|February 10, 2007
Impact of the 16th International Conference on AIDS: can these conferences lead to policy change?Helene Gayle, Mark A Wainberg
AIDS Reviews|June 2, 2006
HIV transmission and primary drug resistanceDan Turner, Mark A Wainberg
AIDS (London, England)|February 16, 2010
Can the further clinical development of bevirimat be justified?Mark A Wainberg, Jan Albert
AIDS Patient Care and Stds|October 9, 2007
Review: immunologic response to protease inhibitor-based highly active antiretroviral therapy: a reviewMark A Wainberg, Bonaventura Clotet
Pageof 35